Who has been buying Medytox stock?

3 distinct insiders have filed 13 disclosed insider purchases in Medytox (086900), most recently on 2026-07-07. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Medytox have?

Medytox has 13 buy-side and 2 sell-side disclosures on record, covering ₩1.8B ($1.2M) in total reported value, spanning 2024-04-11 to 2026-07-07.

Where does StockDrifts get Medytox insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Medytox 086900

Company

메디톡스Medytox

Insiders

Buys

Total Value

₩1.8B ($1.2M)

Avg Return

-7.05%

Last Filing

2026-07-07

Medytox (086900) has 13 disclosed insider purchases and 2 disclosed disposals on record, filed by 3 distinct insiders. Together those filings cover ₩1.8B ($1.2M) in reported transaction value. The earliest filing StockDrifts holds for Medytox is dated 2024-04-11; the most recent is 2026-07-07. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -7.05%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-08-03	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	3.5K	₩72,000	+6.8%	₩245M ($170K)
2026-07-30	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	450	₩70,800	+1.7%	₩32M ($22K)
2026-07-29	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	1.0K	₩68,200	+5.6%	₩74M ($51K)
2026-07-07	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	1.3K	₩74,700	-4.8%	₩94M ($65K)
2026-06-26	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	65	-	-	-
2026-06-25	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	1.3K	-	-	-
2026-03-27	BUY	신규선임	천영익 Youngik Cheon	Outside Director	7.3K	₩103,600	+0.0%	₩761M ($528K)
2026-03-18	BUY	Market Buy	정진향 Jinhyang Jeong	moving	5	₩113,900	-9.0%	₩570K ($395)
2026-03-03	BUY	신규선임	정진향 Jinhyang Jeong	moving	35	₩126,100	-17.8%	₩4M ($3K)
2025-11-03	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	2.5K	₩120,200	+9.4%	₩301M ($209K)
2025-04-07	BUY	신규선임	이인재 Injae Lee	Treatment for directors	1.4K	₩139,000	-5.4%	₩195M ($135K)
2024-08-26	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	1.7K	₩204,000	-35.5%	₩337M ($234K)
2024-08-16	SELL	Market Sell	이재철 Jaechul Lee	moving	-410	₩201,000	+34.6%	₩82M ($57K)
2024-08-16	SELL	Market Sell	이재철 Jaechul Lee	moving	-20	₩201,000	+34.6%	₩4M ($3K)
2024-08-16	BUY	Market Buy	이재철 Jaechul Lee	moving	410	₩201,000	-34.6%	₩82M ($57K)
2024-08-13	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	1.0K	₩183,100	-28.2%	₩183M ($127K)
2024-08-06	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	1.1K	₩164,200	-19.9%	₩181M ($125K)
2024-08-02	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	1.2K	₩165,800	-20.7%	₩199M ($138K)
2024-06-26	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	715	₩147,700	-11.0%	₩106M ($73K)
2024-04-12	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	565	₩137,200	-4.2%	₩78M ($54K)
2024-04-11	BUY	Market Buy	정현호 Hyeonho Jeong	CEO	899	₩134,700	-2.4%	₩121M ($84K)

Frequently asked questions

Who has been buying Medytox stock?: 3 distinct insiders have filed 13 disclosed insider purchases in Medytox (086900), most recently on 2026-07-07. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Medytox have?: Medytox has 13 buy-side and 2 sell-side disclosures on record, covering ₩1.8B ($1.2M) in total reported value, spanning 2024-04-11 to 2026-07-07.
Where does StockDrifts get Medytox insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Medytox. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.